Table 2 Associations of Eph-A5 and -A7 expression with clinicopathological characteristics in 88 NSCLC patients
Clinicopathological characteristics | Eph-A5 expression | Eph-A7 expression | ||||
|---|---|---|---|---|---|---|
Negative/weak | Moderate/high | p-value | Negative/weak | Moderate/high | p-value | |
N = 88 | 37 (42.0) | 51 (58.0) | 38 (43.2) | 50 (56.8) | ||
Age (mean ± SD;ys) | 0.061 | 0.036 | ||||
≤ 64.47 ± 9.18 yrs | 22 (25.0) | 20 (22.7) | 23 (26.1) | 19 (21.6) | ||
> 64.47 ± 9.18 yrs | 15 (17.0) | 31 (35.2) | 15 (17.0) | 31 (35.2) | ||
Gender | 0.333 | 0.287 | ||||
Female | 5 (5.7) | 11 (12.5) | 5 (5.7) | 11 (12.5) | ||
Male | 32 (36.4) | 40 (45.5) | 33 (37.5) | 39 (44.3) | ||
Histopathological type | 0.235 | 0.597 | ||||
Adenocarcimoma | 21 (23.9) | 35 (39.8) | 23 (26.1) | 33 (37.5) | ||
Squamous | 16 (18.2) | 16 (18.2) | 15 (17.0) | 17 (19.3) | ||
Histopathological grade | 0.406 | 0.499 | ||||
I + II | 23 (26.1) | 36 (40.9) | 24 (27.3) | 35 (39.8) | ||
III | 14 (15.9) | 15 (17.0) | 14 (15.9) | 15 (17) | ||
Smoking status | 0.412 | 0.829 | ||||
Yes | 34 (38.6) | 44 (50.0) | 34 (38.6) | 44 (50.0) | ||
No | 3 (3.4) | 7 (8.0) | 4 (4.5) | 6 (6.8) | ||
Alcohol consumption | 0.389 | 0.489 | ||||
Systematic | 23 (26.1) | 27 (30.7) | 20 (22.7) | 30 (34.1) | ||
No systematic | 14 (15.9) | 24 (27.3) | 18 (20.5) | 20 (22.7) | ||
Performance status | 0.369 | 0.626 | ||||
0-1 | 31 (35.2) | 46 (52.3) | 34 (38.6) | 43 (48.9) | ||
2 | 6 (6.8) | 5 (5.7) | 4 (4.5) | 7 (8.0) | ||
Inflammation | 0.297 | 0.529 | ||||
Yes | 6 (6.8) | 13 (14.8) | 7 (8.0) | 12 (13.6) | ||
No | 31 (35.2) | 38 (43.2) | 31 (35.2) | 38 (43.2) | ||
Lymphovascular invasion | 0.328 | 0.403 | ||||
Yes | 13 (14.8) | 13 (14.8) | 13 (14.8) | 13 (14.8) | ||
No | 24 (27.3) | 38 (43.2) | 25 (28.4) | 37 (42.0) | ||
Necrosis | 0.656 | 0.540 | ||||
Yes | 20 (22.7) | 30 (34.1) | 23 (26.1) | 27 (30.7) | ||
No | 17 (19.3) | 21 (23.9) | 15 (17.0) | 23 (26.1) | ||
Fibrosis | 0.879 | 0.029 | ||||
Yes | 7 (8.0) | 9 (10.2) | 3 (3.4) | 13 (14.8) | ||
No | 30 (34.1) | 42 (47.7) | 35 (39.8) | 37 (42.0) | ||
Tumor size | 0.530 | 0.018 | ||||
T1 | 6 (6.8) | 11 (12.5) | 3 (3.4) | 14 (15.9) | ||
T2-4 | 31 (35.2) | 40 (45.5) | 35 (39.8) | 36 (40.9) | ||
Lymph node metastases | 0.302 | 0.179 | ||||
N0-1 | 23 (26.1) | 37 (42.0) | 23 (26.1) | 37 (42.0) | ||
N1-2 | 14 (15.9) | 14 (15.9) | 15 (17.0) | 13 (14.8) | ||
Distant metastases | 0.206 | 0.229 | ||||
M0 | 33 (37.5) | 49 (55.7) | 34 (38.6) | 48 (54.5) | ||
M1 | 4 (4.5) | 2 (2.3) | 4 (4.5) | 2 (2.3) | ||
Histopathological stage | 0.285 | 0.378 | ||||
I + II | 19 (21.6) | 32 (36.4) | 20 (22.7) | 31 (35.2) | ||
III + IV | 18 (20.5) | 19 (21.6) | 18 (20.5) | 19 (21.6) | ||
Ki-67 protein statement | 0.002 | 0.046 | ||||
< mean value | 23 (26.1) | 15 (17.0) | 21 (23.9) | 17 (19.3) | ||
≥ mean value | 14 (15.9) | 36 (40.9) | 17 (19.3) | 33 (37.5) | ||